[{"id":"14f3750f-2561-43de-ada7-a0f09f687fd3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06123884","created_at":"2023-11-09T16:12:40.489Z","updated_at":"2025-02-25T15:28:26.776Z","phase":"Phase 2/3","brief_title":"BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer","source_id_and_acronym":"NCT06123884","lead_sponsor":"Bio-Thera Solutions","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • Avzivi (bevacizumab-tnjn) • BAT1308"],"overall_status":"Recruiting","enrollment":" Enrollment 526","initiation":"Initiation: 12/13/2023","start_date":" 12/13/2023","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-10"},{"id":"e63f0e05-cc7f-4b58-a1ed-3db818ab154b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05155722","created_at":"2021-12-14T13:53:59.604Z","updated_at":"2024-07-02T16:36:18.833Z","phase":"Phase 1","brief_title":"Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT1308 in Advanced Solid Tumors","source_id_and_acronym":"NCT05155722","lead_sponsor":"Bio-Thera Solutions","biomarkers":" PD-L1 • PD-1","pipe":"","alterations":" ","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAT1308"],"overall_status":"Recruiting","enrollment":" Enrollment 148","initiation":"Initiation: 09/17/2020","start_date":" 09/17/2020","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2022-01-05"}]